459 related articles for article (PubMed ID: 20422415)
1. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
3. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
4. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
Ohyashiki JH; Yoneta M; Hisatomi H; Iwabuchi T; Umezu T; Ohyashiki K
BMC Med Genet; 2012 Jan; 13():6. PubMed ID: 22251709
[TBL] [Abstract][Full Text] [Related]
5. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
[TBL] [Abstract][Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
7. JAK2 rs10974944 is associated with both V617F-positive and negative myeloproliferative neoplasms in a Vietnamese population: A potential genetic marker.
Ngoc NT; Hau BB; Vuong NB; Xuan NT
Mol Genet Genomic Med; 2022 Oct; 10(10):e2044. PubMed ID: 35996819
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
9. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
10. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
12. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
13. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
16. Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.
Paes JF; Torres DG; Aquino DC; Alves EVB; Mesquita EA; Sousa MA; Fraiji NA; Passos LNM; Abreu RS; Silva GAV; Tarragô AM; de Souza Mourão LP
Sci Rep; 2024 Apr; 14(1):9389. PubMed ID: 38654055
[TBL] [Abstract][Full Text] [Related]
17. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
18. JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
Tanaka M; Yujiri T; Ito S; Okayama N; Takahashi T; Shinohara K; Azuno Y; Nawata R; Hinoda Y; Tanizawa Y
Int J Hematol; 2013 Mar; 97(3):409-13. PubMed ID: 23430670
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]